Flashcards in Week 9. Basis and classification of haematological malignancies Deck (15):
general info on malignancies?
Monoclonal (polyclonal=reactive events e.g. infections)
Clonal diseases-come from common ancestor.
Cell has mutated leading to malignant transformation.
Resistant to apoptosis
In summary what are the steps causing malignancies?
Toxin, virus infection, drug, genetic predisposition.
Oncogene and tumour suppressor gene
less apoptosis, less differentiation, more proliferation
What causes malignancy?
1. Genetic predisposition:
-downs syndrome- increased incidence of leukaemia.
human t-lymphotropic virus type 1 (HTLV-1)
adult t-cell leukaemia/lymphoma (ATLL)
-Epstein-barr virus- Burkitt's lymphoma
Bacteria- helicobacter pylori infection0 gastric lymphomas.
(if you're infected with these, more likely to get cancer later on)
Acute lymphoblastic leukaemia (ALL)
Exposure to mutagens during pregnancy.
Then need a 2nd transforming event after birth. (unclear mechanism)
Children who went to daycare less likely to develop ALL. Seemed exposed to more infections so better immune system so could respond normally to infection and second transforming event.
In twins if one got ALL usually the other did in the end but not at the same age.
What environmental things can cause malignancies?
1. Ionizing radiation, cauding mutations
2. Chemicals: benzene (chronic)- chromosomal abnormalities in leukaemia.
3. Drugs: Alkalyting agents, e.g. chlorambucil-myeoloid leukaemia.
What is the mechanism of malignancy?
Dysregulation of oncogenes and tumour suppressor genes. Oncogenes gain function, tumour suppressor lose function- can;t suppress
Derived from proto-oncogenes
Gain of function mutation: amplification, point mutations or chromosomal translocations.
Blockage of differentiation OR
Prevention of apoptosis
End up with malignant cells that aren't fully functional
Tumour suppressor genes (TSG)
Commonly involved in cell cycle
Inactivation of a tumour-suppressor gene:
-by deletion or mutation
-loss of function mutations
-promotes malignant transformation
Encode for proteins that negatively regulate proliferation.
p53 most significant TSG in human cancers (50%)
Frequent genetic mutations/abnormalities in leukaemia and lymphoma
AML- t(15;17)- oncogene= RARalpha, PML
CML- t(9;22)- oncogene= ABL,BCR
Follicular lymphoma t(14;18) oncogene= BCL-2 to IgH
What are the 3 main roles of genetic markers in haematological malignancies?
3.Monitoring minimal residual disease: aim is to put them into remission. May not be free of cancer but below detection.
Haematological malignancy diagnosis?
Genetic abnormalities (e.g.t(15;17))
-specific for particular disease.
Clonal immunoglobulin or T cell receptor (TCR) rearrangments.
-establishing if malignancy is T or B cell lineage.
Haematological malignancy sub-classification?
Presence of a particular translocation
t(14;18) in diffuse-large B cell lymphoma
prognastic info for this group of patients
Haemattological malignancy montioring minimal residual disease?
Monitoring minimal residual disease:
-low level of disease detactable with some methods
-can have approx. 10^13-10^14 malignant cells
-can use PCR
-patient in remission when less than 5% of blasts detected in the bone marrow.
Lab techniques to assess malignant cells?
1. Karyotype analysis: morphological analysis of chromosomes from tumour cells under the microscope
2. Fluorescent in situ hybridization analysis:
analyse expression of genes, bind specific parts of genome, tags anneal DNA, detect extra copied of genetic material
3.Southern blot analysis: If translocation has occured, will see novel band on gel. Time consuming.
4. PCR: detect chromosomal translocation. Determine presence of clonal cells in B and T cell malignancies.